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Summary Plasmid-mediated class C b-lactamases are reported from Enterobacteriaceae with
increasing frequency. They likely originate from chromosomal AmpC of certain Gram-negative
bacterial species and subsequently are mobilized onto transmissible plasmids. There are reports
of unfavorable clinical outcomes in patients infected with these organisms and treated with
broad-spectrum cephalosporins. However, unlike class A extended-spectrum b-lactamases
(ESBLs), no screening and confirmatory tests have been uniformly established for strains that
produce class C b-lactamases. Reduced susceptibility to cefoxitin is a sensitive but not specific
indicator of class C b-lactamase production. Simple confirmatory tests including tests using
boronic acid compounds as specific class C b-lactamase inhibitors have recently been developed.
Their utilization will enable clinical microbiology laboratories to report those strains producing
plasmid-mediated class C b-lactamases as being resistant to all broad-spectrum cephalosporins,
thus allowing physicians to prescribe appropriate antimicrobial therapy.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
b-Lactamases are produced by many bacterial species as a
means of self-defense against b-lactam antimicrobials, such
as penicillins, cephalosporins and carbapenems. There are
four molecular classes of b-lactamases. Class A, C and D b-
lactamases possess an active-site serine, whereas class B b-
lactamases are metalloenzymes usually requiring a zinc
molecule for their catalytic activities.1,2 Detection of differ-
ent classes of b-lactamases in b-lactam-resistant Gram-
negative bacteria is of paramount clinical importance, since
it can often provide valuable information to clinicians leading* Corresponding author. Tel.: +1 412 647 6478; fax: +1 412 647 6399.
E-mail address: patersond@dom.pitt.edu (D.L. Paterson).
1201-9712/$32.00 # 2007 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2006.07.008to more effective and appropriate use of antimicrobials.3,4
Also, it serves as a powerful epidemiologic tool from the
infection-control standpoint.5
Methods to screen for and confirm production of class A
extended-spectrum b-lactamases (ESBLs) and class B
metallo-b-lactamases (MBLs) have been established and uti-
lized clinically. The methodology to detect ESBLs among
Klebsiella pneumoniae, Klebsiella oxytoca, Escherichia coli
and Proteus mirabilis in clinical microbiology laboratories is
validated and endorsed by the Clinical Laboratory Standards
Institute (CLSI).6 In brief, it is composed of screening for
diminished susceptibility to a third-generation cephalosporin
or aztreonam followed by confirmation, which tests for the
presence of an inhibitory effect by clavulanic acid, a class A
b-lactamase inhibitor, against the antimicrobial activity of
ceftazidime and cefotaxime. Simple methods to detect MBLPublished by Elsevier Ltd. All rights reserved.
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Table 1 Rationale for detection of plasmid-mediated class
C b-lactamases
Increasing prevalence in the USA and probably worldwide
(paucity of data on prevalence outside the USA)
Infection control opportunities for prevention of spread of
important mechanisms of plasmid-mediated multi-drug
resistance
Potential treatment failure with broad-spectrum cephalospor-
ins since laboratories may report plasmid-mediated class C
producers as susceptible to broad-spectrum cephalosporins
using conventional CLSI breakpoints
Plasmid-mediated class C producers may appear susceptible
using conventional CLSI breakpoints yet meet CLSI screening
breakpoints for ESBLs. Since they will be negative by pheno-
typic confirmatory tests for ESBLs, they will be erroneously
reported as susceptible to broad-spectrum cephalosporins
CLSI, Clinical and Laboratory Standards Institute; ESBL,
extended-spectrum b-lactamases.production utilize specific inhibitors such as mercaptoacetic
acid or EDTA, which are tested against ceftazidime or imi-
penem.7,8 These detection methods for ESBLs and MBLs are
available in different formats including broth microdilution,
disk diffusion, and Etest.
On the other hand, methods to detect class C and D b-
lactamases have not been as well established. In particular,
class C b-lactamases, whose genes used to be confined to the
chromosome of various Gram-negative species as ampC, have
disseminated worldwide on plasmids since the late 1980s and
now represent a substantial clinical threat.9,10 Their pre-
sence renders the bacteria resistant to most b-lactams
including cephamycins and b-lactam/b-lactamase combina-
tions, which are generally stable against ESBLs. Due to the
lack of simple and reliable detection methods for class C b-
lactamases that can be undertaken in clinical laboratories,
their exact prevalence is unknown. Nevertheless, plasmid-
mediated AmpC was found in 8.5% to 11% of ceftazidime-
resistant K. pneumoniae isolates in recent nationwide sur-
veys performed in the USA.11,12
It is important to note that many organisms producing
class C b-lactamases may not be resistant to broad-spectrum
cephalosporins when conventional CLSI breakpoints are used.
Yet, adverse clinical outcomes in patients with infections
caused by organisms producing plasmid-mediated class C b-
lactamases have been reported when these patients were
treated with cephalosporins.13 Specifically, in this study,
patients who were treated with broad-spectrum cephalos-
porins rather than carbapenems had higher mortality rates.
The inoculum effect, well-known to ESBL-producing organ-
isms, has been demonstrated among organisms producing
some of the plasmid-mediated class C b-lactamases, poten-
tially providing one explanation for the less reliable outcome
when cephalosporins were used.14,15
Of great importance is that organisms producing plasmid-
mediated class C enzymes typically yield negative confirma-
tory tests for ESBL production by the current CLSI criteria.
Therefore the susceptibilities will be reported ‘as they are’
(that is, apparently susceptible results for cephalosporins
will not be changed to resistant, as is the case for ESBL
producers). Hence, there has been a growing interest in
developing convenient methods to detect production of
plasmid-mediated class C b-lactamases by Gram-negative
bacteria so that ‘susceptible’ results can be reported as
‘resistant’, as is the case with ESBL producers (Table 1).
The most clinically important species are K. pneumoniae, E.
coli, P. mirabilis and Salmonella serovars that lack chromo-
somal AmpC as well as E. coli that only expresses its chro-
mosomal AmpC at a basal level due to the lack of strong
promoter activity.
Conjugation or transformation experiments are required
to confirm the location of the b-lactamase genes on plasmids;
such tests can only be undertaken in a reference laboratory
and hence are not clinically useful. Detection of class C b-
lactamase production in the species mentioned above almost
always indicates exogenous origin of the genes, as they either
lack or typically produce only basal amounts of AmpC, as
mentioned above. Also, they are the species from which the
majority of plasmid-mediated class C b-lactamases have
been reported.9,10 The purpose of this article is to review
the various phenotypic and genetic methods that have been
described to detect plasmid-mediated class C b-lactamases.Susceptibility patterns of class C
b-lactamase-producing organisms
Although genetically diverse, production of chromosomal or
plasmid-mediated class C b-lactamases can be inferred to a
certain extent from routine susceptibility testing patterns to
several b-lactam agents. Unlike class A b-lactamases includ-
ing ESBLs, class C b-lactamases are known to utilize 7a-
methoxy-cephalosporins, or cephamycins, such as cefoxitin
or cefotetan, as substrates.16,17 Therefore, cefoxitin resis-
tance in Enterobacteriaceae combined with resistance to an
oxyimino-cephalosporin such as ceftazidime is often indica-
tive of class C b-lactamase production.18,19 This method is
sensitive in ruling in class C b-lactamase producers among K.
pneumoniae and E. coli, but not specific since some ESBL-
producing organisms may have elevated cefoxitin minimum
inhibitory concentrations (MICs).11,12,20 Decreased produc-
tion of outer membrane proteins has been demonstrated as
the cause of non-susceptibility to cefoxitin in clinical isolates
of K. pneumoniae and E. coli.21,22 AAC-type class C b-lacta-
mases, originating from the chromosome of Hafnia alvei, are
known to poorly inactivate cephamycins and are an exception
to the rule of cephamycin resistance.23 Also, efflux and
impermeability of cefoxitin render this method less useful
in lactose-non-fermenting Gram-negative species.
Commercially available b-lactamase inhibitors including
clavulanate, sulbactam and tazobactam poorly inhibit class C
b-lactamases, and therefore lack of inhibition when these
agents are combined with b-lactam substrates may be sug-
gestive of class C b-lactamase production, although this may
occur with inhibitor-resistant TEM (IRT) b-lactamases belong-
ing to class A as well.18,24 Additionally, some organisms that
produce class A b-lactamases including ESBLs are resistant to
b-lactam/b-lactamase inhibitor combinations such as ampi-
cillin/sulbactam, amoxicillin/clavulanate and piperacillin/
tazobactam.4 The potential reasons for this include hyper-
production of ESBL, TEM-1 or SHV-1 enzymes,25 production of
IRT b-lactamases derived from TEM-1,26 co-production of
class D OXA-type enzymes,27,28 and co-production of class
C b-lactamases, especially AmpC in the case of E. coli.26
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Table 2 Characteristics of screening and confirmatory tests for detection of plasmid-mediated class C beta-lactamases
Tests Characteristics
Screening tests
Decreased susceptibility to
expanded-spectrum cephalosporins
and resistance to cefoxitin
 Highly sensitive but nonspecific
 May rule in strains with decreased outer
membrane production or chromosomal
AmpC hyperproducers in E. coli.
Decreased susceptibility to
expanded-spectrum cephalosporins
and lack of inhibition by b-lactamase
inhibitors
 Highly sensitive but nonspecific
 May represent production of class B or
D b-lactamase, IRTs, or hyperproduction
of ESBLs
Decreased susceptibility to
expanded-spectrum cephalosporins
but retained susceptibility to cefepime
or cefpirome
 Poorly sensitive and specific
 May miss co-production of ESBLs
Confirmatory tests
Three-dimensional test  First phenotypic confirmatory test to
be described
 Technically demanding
AmpC disk test  Easier to perform than three-dimensional
test, but slightly more complicated than
inhibitor-based tests
3-Aminophenylboronic acid (APB)-based
disk/microdilution test
 Easy to perform as analogous to ESBL
confirmatory test
 Potential to be incorporated into
automated susceptibility testing systems
Benzo[b]thiophene-2-boronic acid
(BZBTH2B)-based disk test
 Improved sensitivity when combined
with clavulanic acid
Multiplex PCR  Able to differentiate plasmid-borne
class C b-lactamase from chromosomal ones
 Limited availability
IRT, inhibitor-resistant TEM; ESBL, extended-spectrum b-lactamases.An attempt was made to establish an algorithm to identify
class C b-lactamase producers among Enterobacteriaceae
with the use of available disks containing broad-spectrum
cephalosporins and b-lactamase inhibitors.29 Though the
investigators could not select definitive interpretive criteria,
resistance to cefpodoxime followed by a negative inhibitory
test combining clavulanate and cefpodoxime or ceftriaxone
correlated with production of class C b-lactamase.
Another criterion that may be used is susceptibility to
zwitterionic, or fourth-generation, cephalosporins such as
cefepime and cefpirome. Class C b-lactamases do not hydro-
lyze them efficiently, and MIC values remain low unless there
is concomitant production of ESBLs.9 A recent study of
ceftazidime-resistant Enterobacter cloacae strains suggested
that a cefepime MIC of less than 2 mg/ml was indicative of
class C b-lactamase rather than ESBL production.30 However,
a plasmid-mediated b-lactamase CMY-19, conferring low-
grade cefepime resistance (MIC 4 mg/ml), was recently iden-
tified in K. pneumoniae.63 This change in substrate profile
was due to an amino acid substitution in the H-10 helix
region. The susceptibility profile of class C b-lactamase-
producing organisms against cefepime will therefore require
continuous monitoring.
None of the above methods are confirmatory, but taken
together, a clinical laboratory may be able to screen for
strains producing class C b-lactamases, especially amongK. pneumoniae, K. oxytoca, E. coli, P. mirabilis and Salmo-
nella serovars, which either lack or minimally express chro-
mosomal AmpC b-lactamase, and even other species in
Enterobacteriaceae producing chromosomal AmpC of various
amounts (Table 2). Strains with plasmid-mediated class C b-
lactamases should be resistant to both cephamycins and b-
lactam/b-lactamase inhibitor combinations, although the
specificity of these findings appears to be poor. This necessi-
tates use of phenotypic confirmatory tests in such strains.
Phenotypic confirmatory tests
Three-dimensional tests
Because of the paucity of specific inhibitors against class C b-
lactamases, phenotypic confirmation of class C b-lactamase
production has long relied on an inhibition test termed the
three-dimensional test, which was originally developed to
detect both ESBLs and class C b-lactamases.31 In this method,
a slit is created in the agar next to and away from the disks at
the end of the standard disk diffusion procedure for suscept-
ibility testing. The slit is then inoculated with broth contain-
ing the test organism. After an overnight incubation,
enzymatic inactivation of the antimicrobial is detected by
inspecting the margin of the inhibition zone at the intersec-
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usually circular inhibition zone is indicative of inactivation of
the test drug, which occurs as a result of diffusion of b-
lactamase through the agar from the organism in the three-
dimensional slit.
In a study by Thomson and Sanders, when the surface of
the plate was inoculated with a susceptible organism, e.g. E.
coli ATCC 25922, instead of the test organism itself, and a
cefoxitin disk was used, production of a class C b-lactamase,
MIR-1, was visually discernable.31 While technically demand-
ing, this report formed the basis for subsequent modifications
of the three-dimensional test in an attempt to make the
procedure simpler and more reproducible.
When the three-dimensional test was performed with
crude enzyme extract in place of live bacterial inoculum
to fill the slit, in combination with a cefoxitin disk, both high
sensitivities and specificities were reported in detecting class
C b-lactamase production among E. coli, K. pneumoniae and
P. mirabilis.32 Despite the excellent results reported, this
modification remained labor-intensive and required avail-
ability of a centrifuge as well.32,33
This process was simplified a great deal with the AmpC disk
test.34 In brief, an agar plate is inoculatedwith a lawnof E. coli
ATCC 25922 and a cefoxitin disk is placed. Then, several colo-
nies of the test organismare applied toan ‘AmpCdisk’ contain-
ing Tris—EDTA and placed almost touching the cefoxitin disk.
This modification dispensed with the enzyme extraction pro-
cess sinceTris—EDTApermeabilizesbacterial cells and releases
b-lactamases into the external environment. A positive result
is indentation or flattening of the zone of inhibition indicating
enzymatic inactivation of cefoxitin. This test showed sensitiv-
ity of 100% and specificity of 90% in detecting class C b-
lactamases when compared against the combination of iso-
electric focusing and multiplex PCR as the gold standard. The
utility of this method was confirmed by other investigators.35
In a cefoxitin-agar medium-based assay, a circular well
was made in the agar, which was then filled with crude
enzyme of the test strain.36 A zone of growth of E. coli ATCC
25922 around the periphery of a well was considered positive.
This method showed 100% concordance with a conventional
three-dimensional test when a cefoxitin concentration of
4 mg/ml was used in the agar. While interpretation of a
positive test would be more straightforward than in the other
tests, it can only be carried out at a laboratory equipped with
a centrifuge. A more convenient spot inoculation method has
also been proposed,37 but confirmation using crude enzyme is
recommended for indeterminate cases, and the utility of the
method remains unclear at this time.
Interestingly, while another modification of the three-
dimensional test termed the cefoxitin-Hodge test, where a
test strain is streaked on the agar directly and away from the
cefoxitin disk without use of slit or well, was able to detect
CMY-10-type plasmid-mediated class C b-lactamases well, it
had low sensitivity against DHA-1-type enzymes, indicating
that continued evaluation of these enzyme-based methods
with diverse and larger number of class C b-lactamases may
be warranted.38
Inhibitor-based tests
Efforts to synthesize inhibitors specific to class C b-lacta-
mases have yielded numerous compounds, some b-lactam-based and others non-b-lactam. While none of these newer
compounds have been made available for therapeutic pur-
poses yet, their potential use for laboratory detection of
class C b-lactamases can certainly be explored.
Several new molecules have been evaluated as class C b-
lactamase inhibitors. One of the first of these compounds was
BRL42715, a penem containing an alkylidenemoiety at the C6
position of the b-lactam ring, which was found to be a potent
inhibitor of class C as well as class A b-lactamases.39 Unfor-
tunately its development was dropped later due to ineffec-
tive penetration of outer membranes into the periplasmic
space and its role in the detection of b-lactamases was not
evaluated.40
Ro 48-1220, a 2b-alkenyl penicillanic acid sulfone, inhibits
class A andCb-lactamases.41,42 At a concentrationof 4 mg/ml,
it reduced the MICs of ceftazidime against producers of class C
b-lactamases by four- to 64-fold.42 It was first utilized in a disk
method for confirmation of class C enzyme production in
Salmonella serovar Enteritidis producing DHA-1.43 Disks con-
taining cefotetan and Ro 48-1220 placed 30 mmapart gave the
best discernable result.43 When applied to the standard broth
microdilution method, addition of Ro 48-1220 at 4 mg/ml
decreased the MIC of cefoxitin by at least four-fold for 11 of
16 class C producers.32 The compound was evaluated for the
disk potentiation test as well.44 An increase of4 mm in zone
diameter in the presence of 20 mg of Ro 48-1220, when cefo-
tetan was used as the substrate, identified class C b-lacta-
mase-producing strains with high sensitivity and specificity.44
The specificity of the test decreased when non-cephamycin
cephalosporinswereusedas the substrates, sinceRo 48-1220 is
a potent inhibitor of class A enzymes as well.
Syn2190 is a 1,5-dihydroxy-4-pyridone monobactam with
potent inhibitory activity against class C b-lactamases but
negligible activity against class A enzymes.45 Its use for detec-
tion of class C enzymeproduction in a double-disk potentiation
method has been attempted.46 However, interpretation of the
results was difficult when disks containing Syn2190 and cefox-
itin were placed in proximity to maintain sensitivity.46 Evalua-
tion of its use in different methods may be beneficial.
Several other b-lactam-based inhibitors with activity
against class C enzymes have been synthesized, including a
bridged monobactam Ro 48-1256,47 C3-substituted cephalos-
porin sulfones,48 oxapenem compounds,49 and methylidene
penems,50,51 but none of them have been assessed for use for
the purpose of b-lactamase detection.
Among non-b-lactam inhibitors, boronic acid compounds
are among the best studied. Boronic acids were long known to
have inhibitory effects against class C b-lactamases.52 Sub-
sequently, benzo[b]thiophene-2-boronic acid (BZBTH2B) was
identified as a highly potent inhibitor of E. coli AmpC,53,54 as
well as carboxyphenylglycyl boronic acids and aza-boronic
acids.55,56 BZBTH2B was used first for phenotypic detection
of class C enzyme production.57 On an agar plate with a lawn
of the test strain, a disk containing 64 mg of BZBTH2B was
placed between cefoxitin and ceftazidime disks, which con-
firmed the presence of class C b-lactamase in a Salmonella
strain and several E. coli strains by expansion of inhibitory
zones of the disks with substrate b-lactams facing the
BZBTH2B disk.57 Methods using 3-aminophenylboronic acid
(APB) were then developed.58 In the experiments, the disk
potentiation test, double-disk synergy test and microdilution
test were evaluated in K. pneumoniae and E. coli strains
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Figure 1 Suggested phenotypic approach for screening for and
confirming b-lactamase classes.producing various plasmid-mediated class C enzymes. When
300 mg/ml of APB and the same interpretive criteria as those
for detection of ESBLs as defined by CLSI were used,6 all three
methods were shown to have excellent sensitivity and speci-
ficity.58 A combination of a cefotetandisk and a disk containing
120 mg of phenylboronic acid yielded comparable results in the
disk potentiation test but the brothmicrodilution test was less
sensitive.59 Other investigators further evaluated BZBTH2B at
the same concentration for use in disk potentiation.60 Cefpo-
doxime was used as the substrate, and improved sensitivity
was demonstrated when BZBTH2B was combined with clavu-
lanic acid. Thiswas likely due to the suppression of the activity
of concomitantly produced ESBLs.60
Our suggested approach to phenotypic classification of
clinically important b-lactamases is shown in Figure 1. All the
tests used in the Figure can be performed by simple disk
diffusion methods or Etests in the clinical laboratory.
Depending on local prevalence data, the order may be
modified, or some tests may be performed simultaneously
to decrease reporting time.
Genetic and immunologic tests
Six genetically diverse families are known to exist among
plasmid-mediated class C b-lactamases.9 Multiplex PCR using
a total of six primer sets for each family has been devel-oped.61 Because of requirements for equipment, labor-inten-
siveness, and high costs, its use has been limited mainly to
reference laboratories. However, it has the advantage of
being able to detect the plasmid-mediated class C b-lacta-
mase gene even in species carrying the chromosomal ampC
gene, given that the gene on the plasmid does not derive
from the same species.
An ELISA which utilizes a polyclonal antibody against CMY-
2, which is a common plasmid-mediated class C b-lactamase
in Salmonella serovars and E. coli, has been produced.62 It
was able to detect many of the class C enzymes belonging to
other families as well when higher concentrations were
used.62 Its use remains within research settings at this time.
Summary
Plasmid-mediated class C b-lactamases, originally reported in
the late 1980s, have now spread worldwide. Most of their
structural genes are believed to have transferred from chro-
mosomal ampC genes and disseminated subsequently. Reports
on adverse clinical outcomes in patients infected with the
producing organisms are emerging. They may not necessarily
confer resistance to broad-spectrum cephalosporins when
conventional CLSI breakpoints are used, although they may
meet screening criteria for ESBLs. They typically have a nega-
tive confirmatory test for ESBLs and therefore laboratories
may report AmpC producers as susceptible to broad-spectrum
cephalosporins. This may have disastrous consequences if
physicians erroneously use broad-spectrum cephalosporins
to treat serious infections such as bacteremia. It is imperative,
however, that Gram-negative bacteria producing plasmid-
mediated class C b-lactamases are detected and reported
adequately so that appropriate antimicrobial therapy and
infection control measures can be initiated. Fortunately, sev-
eral simple detection methods of class C b-lactamases have
been reported recently. When ESBL production is suspected
but the confirmatory tests are negative, the strains should be
screened for the presence of class Cb-lactamase, especially in
species lacking chromosomal AmpC b-lactamase. The ‘AmpC
disk test’ or inhibitor-based tests,mostpractically thosebased
on boronic acid compounds, may be incorporated into ESBL
detection algorithms upon further evaluation and verification,
asmoredataonclinical implicationsofplasmid-mediatedclass
C b-lactamases accumulate.
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